|
Forecast
Period
|
2026-2030
|
|
Market
Size (2024)
|
USD
4.56 Billion
|
|
Market
Size (2030)
|
USD
8.12 Billion
|
|
CAGR
(2025-2030)
|
10.21%
|
|
Fastest
Growing Segment
|
Consumables
|
|
Largest
Market
|
North India
|
Market Overview
India Cancer Diagnostics Market was valued at USD 4.56 billion in 2024 and is expected to reach USD 8.12 billion by 2030, growing with a CAGR of 10.21% in the forecast
period. The cancer diagnostics market in India is experiencing robust growth, driven by a combination of lifestyle changes, increasing health awareness, and advancements in healthcare infrastructure. As individuals become more conscious of their well-being, there is a rising focus on early detection and preventive healthcare. The growing prevalence of cancer, coupled with a heightened emphasis on timely diagnosis, is encouraging the adoption of sophisticated diagnostic tools across the country. Modern lifestyles, marked by high stress and limited time for regular health checkups, often lead to delays in disease detection. This has increased the demand for accurate and accessible diagnostic solutions that can identify cancer at an early stage. As a result, more people are turning to specialized cancer diagnostics to ensure effective monitoring of their health, especially as early diagnosis significantly improves treatment outcomes.
In addition, rising healthcare expenditure and ongoing investments in medical technologies are further propelling the market forward. The expanding network of diagnostic laboratories and the integration of advanced techniques such as molecular diagnostics, imaging, and biomarker testing are also enhancing the scope of cancer detection. India’s aging population is playing a crucial role in driving demand. Older adults are more susceptible to chronic conditions like cancer, and they increasingly rely on reliable diagnostic services to manage their health proactively. The Indian cancer diagnostics market is poised for significant expansion, supported by a blend of technological innovation, demographic shifts, and a growing culture of health consciousness.
Key Market Drivers
Increasing Cancer Incidence
India has witnessed a rising incidence of cancer,
partly due to lifestyle factors, environmental pollution, and an aging
population. India's population has been steadily growing, and with it, the
proportion of elderly individuals. Aging is a well-known risk factor for
cancer, as cellular changes over time can increase the likelihood of
malignancies. This demographic shift has contributed to the increased cancer
burden in the country. For instance, in May 2025, a report by the National Academy of Medical Sciences (NAMS) highlighted that inadequate diagnostic services remained a critical gap in cancer care in India. It stated that patients in India often presented with later-stage disease compared to those in Western countries. The report also noted that nearly 200,000 new cancer cases were reported annually, underscoring the urgent need for improved early detection and diagnostic infrastructure.
Urbanization and the adoption of Western lifestyles
have brought about significant changes in dietary habits and physical activity
levels among Indians. Diets high in processed foods, low in fruits and
vegetables, and sedentary lifestyles are associated with higher cancer risk.
The prevalence of these factors has contributed to the rising cancer incidence.
Environmental pollution, exposure to carcinogens, and industrialization have
led to increased cancer risk. Pollutants such as air pollutants, pesticides,
and chemicals in groundwater can contribute to the development of cancer. As
industrialization continues, these environmental factors become more
pronounced. A lack of awareness about cancer symptoms and the importance of
regular screenings has delayed diagnoses in many cases. Late-stage cancer
diagnoses often result in more aggressive treatment and poorer outcomes. As
awareness campaigns increase, more individuals are seeking early detection,
which is a positive step toward mitigating the impact of cancer.
The escalating cancer incidence in India has
profound implications for the cancer diagnostics market in the country. With
more individuals at risk of cancer, there is a growing demand for diagnostic services.
This includes screening tests, imaging studies, and laboratory diagnostics.
Healthcare providers are investing in advanced diagnostic technologies to meet
this demand. To keep pace with the rising cancer burden, there have been
significant advancements in diagnostic technologies. From state-of-the-art
imaging modalities to molecular diagnostics, these innovations aid in early
detection and precise diagnosis, improving patient outcomes. The surge in
cancer incidence has prompted increased investments in cancer research and
development in India. This includes the development of new diagnostic tests,
therapies, and treatment modalities. As a result, the cancer diagnostics market
is becoming more robust and competitive. The increasing cancer incidence in
India presents substantial growth opportunities for companies operating in the
cancer diagnostics sector. Market players are expanding their portfolios,
collaborating with research institutions, and enhancing their presence to cater
to the growing demand for diagnostic solutions.
Awareness and Early Detection
Growing awareness about cancer and the importance
of early detection has led to more people seeking diagnostic services. Awareness
campaigns and initiatives have played a pivotal role in educating the Indian
population about cancer and the importance of early detection. Various
non-governmental organizations (NGOs), healthcare institutions, and government
bodies have been actively involved in raising awareness about cancer risk
factors, symptoms, and available screening methods. These efforts have led to a
noticeable shift in public perception and behavior.
One of the significant challenges in India's battle
against cancer has been the prevailing cultural and social stigmas associated
with the disease. Historically, cancer was often considered a taboo topic,
leading to delayed healthcare seeking behavior. However, increased awareness
campaigns have helped change societal mindsets. People are now more open to
discussing cancer, which has led to earlier diagnosis and treatment. In
response to the rising cancer incidence, India has seen the implementation of
various early detection programs. These programs target specific types of
cancer that are prevalent in certain regions or among particular demographics.
Examples include breast cancer screening camps for women and tobacco cessation
programs for high-risk populations. These initiatives aim to catch cancer at
its earliest, most treatable stages.
Awareness campaigns have not only educated the
public but have also paved the way for improved access to cancer screening
services. Mobile cancer screening units, diagnostic clinics, and specialized
cancer centers have become more prevalent. This increased accessibility ensures
that individuals can undergo necessary screenings conveniently and affordably. Early
detection is often synonymous with improved patient outcomes in cancer cases.
When cancer is identified in its early stages, it is typically more treatable,
and the chances of complete remission are significantly higher. This positive
correlation between early detection and better survival rates has motivated
individuals to seek screenings and healthcare providers to invest in advanced
diagnostic technologies.
The heightened awareness about cancer and the
importance of early detection has led to a surge in demand for cancer screening
services. This includes screenings for breast cancer, cervical cancer,
colorectal cancer, and other prevalent types. As more individuals recognize the
value of early diagnosis, the market for cancer diagnostic tests and procedures
continues to expand. To cater to the growing demand for early cancer detection,
the market has witnessed the development of specialized diagnostic tests. These
tests are designed for early-stage cancer detection and offer higher
sensitivity and specificity. Examples include liquid biopsy tests for detecting
circulating tumor DNA, which can identify cancer at its earliest stages. Healthcare
institutions and diagnostic service providers have recognized the need to
invest in screening infrastructure. This includes acquiring state-of-the-art
imaging equipment, laboratory facilities, and skilled personnel to meet the
rising demand for cancer screenings. Such investments not only improve
diagnostic accuracy but also contribute to market growth. Companies operating
in the cancer diagnostics sector have increasingly collaborated with healthcare
organizations and NGOs to support awareness campaigns. These partnerships
amplify the reach of awareness initiatives and drive more individuals to seek
early detection services, further fueling market growth.
Advancements in Technology
The availability of advanced diagnostic
technologies and tools has improved the accuracy and precision of cancer
diagnostics. the key areas where technological advancements have made a
significant impact in cancer diagnostics is medical imaging. For instance, in April 2025, Indian company Unimeditrek Pvt. Ltd., which produced histopathology laboratory equipment, received FDA clearance for its entire line of diagnostic equipment. This achievement marked a significant milestone in improving the management of cancer and other deadly diseases in India. The clearance validated the company's technological capabilities and opened new opportunities for enhancing diagnostic standards and accessibility across the country’s healthcare system. High-resolution
imaging techniques such as Magnetic Resonance Imaging (MRI), Computed
Tomography (CT) scans, and Positron Emission Tomography (PET) scans have
undergone substantial improvements. These innovations provide detailed insights
into the structure and function of tissues, aiding in early cancer detection
and precise diagnosis. Advances in molecular diagnostics have revolutionized
cancer detection and treatment. Techniques like Polymerase Chain Reaction (PCR)
and Next-Generation Sequencing (NGS) allow for the analysis of genetic and
molecular markers associated with cancer. This enables healthcare providers to
identify specific mutations and tailor treatments to individual patients,
leading to more effective therapies and better outcomes.
Liquid biopsies represent a groundbreaking
advancement in cancer diagnostics. These non-invasive tests analyze circulating
tumor DNA (ctDNA) or other biomarkers present in bodily fluids like blood.
Liquid biopsies offer a minimally invasive way to detect and monitor cancer,
making them particularly valuable for early diagnosis and tracking treatment
response. The integration of AI and machine learning algorithms into cancer
diagnostics has enhanced the accuracy and efficiency of data analysis. These
technologies can analyze vast amounts of medical data, identify patterns, and
assist radiologists and pathologists in interpreting imaging and pathology
reports. This not only reduces human error but also speeds up the diagnostic
process. The COVID-19 pandemic accelerated the adoption of telemedicine and
remote consultations in healthcare, including cancer diagnostics. Patients can
now connect with oncologists and specialists remotely, allowing for timely
consultations, follow-ups, and treatment planning. This technology-driven
approach has improved access to cancer care, especially in remote or
underserved areas. Advancements in point-of-care testing have enabled rapid and
accurate cancer diagnosis at the patient's bedside or in smaller healthcare
facilities. These portable devices can detect cancer biomarkers quickly,
reducing the time required for diagnosis and enabling immediate treatment
decisions.
The integration of advanced technologies in cancer
diagnostics has significantly improved diagnostic accuracy. This is crucial for
identifying cancer at its earliest, most treatable stages, and for guiding
personalized treatment strategies. Patients can benefit from more precise
diagnoses and tailored therapies, ultimately leading to better outcomes. Technological
advancements have led to faster turnaround times for diagnostic tests. Rapid
and efficient testing processes ensure that patients receive timely results,
enabling prompt initiation of treatment when necessary. This speed is
particularly critical in cancer diagnosis, where early intervention can be
lifesaving. The growing demand for technologically advanced cancer diagnostics
has spurred market expansion in India. Companies specializing in diagnostic
equipment, software, and services have witnessed increased demand for their
products. This has led to greater investments in research and development,
further driving innovation in the sector. Technological advancements have also
improved the accessibility of cancer diagnostics. Telemedicine and
point-of-care testing have made it easier for individuals in remote or
underserved areas to access quality diagnostic services. This broader outreach
helps in early detection and ensures that more patients receive appropriate
care. Indian healthcare institutions and diagnostic companies are increasingly
collaborating with global technology leaders to adopt and implement
cutting-edge diagnostic solutions. This collaboration not only enhances the
quality of cancer diagnostics but also fosters international partnerships that
benefit the Indian healthcare ecosystem.
Government Initiatives
Initiatives such as the National Cancer Control
Programme (NCCP) and Ayushman Bharat have increased access to cancer
diagnostics and treatment. The cornerstone of government efforts in India's
fight against cancer is the National Cancer Control Program (NCCP). This
comprehensive initiative aims to combat cancer through prevention, early
detection, treatment, and palliative care. Also, in June 2025, Pune: A mobile cancer-detecting van made rounds through rural areas, offering critical diagnostic services to underserved communities. The initiative aimed to identify cancer at an early stage among villagers who had limited access to healthcare facilities. Equipped with modern screening tools and staffed by trained medical professionals, the van played a key role in raising awareness and improving early detection rates in remote regions of the district.
The government conducts extensive awareness
campaigns to educate the public about cancer risk factors, symptoms, and the
importance of early detection. These campaigns have been instrumental in
changing public attitudes and behaviors regarding cancer. NCCP supports the
implementation of cancer screening programs, such as breast cancer and cervical
cancer screenings for women. These initiatives aim to catch cancer at its early
stages when treatment is more effective. The government invests in building and
upgrading cancer treatment infrastructure, including cancer hospitals and
radiation therapy centers. This infrastructure expansion ensures that more
patients have access to quality cancer care. NCCP fosters research in cancer
prevention, diagnosis, and treatment. It also supports training programs for
healthcare professionals to enhance cancer management capabilities.
National Program for Prevention and Control of
Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS)
Under the NPCDCS, the government targets the
prevention and control of not only cancer but also other non-communicable
diseases. The program integrates cancer control efforts with the broader
context of non-communicable disease control. This ensures a holistic approach
to healthcare. The government invests in the training of healthcare workers,
equipping them with the knowledge and skills needed for cancer screening,
diagnosis, and treatment. NPCDCS provides financial support to states for
implementing cancer control activities, including screening and treatment
services.
Government initiatives, especially those related to
awareness and early detection, have led to a surge in demand for cancer
diagnostic services. As more individuals become aware of the importance of
screenings, the market for diagnostic tests and procedures has grown
significantly. Government investments in healthcare infrastructure have
expanded the availability of diagnostic facilities across the country. This
includes the establishment of cancer screening centers, diagnostic labs, and
radiology facilities. The improved infrastructure contributes to market growth.
Government programs often encourage collaboration between public and private
healthcare sectors. Diagnostic companies have opportunities to partner with
government agencies to provide testing services, equipment, and expertise. Such
collaborations can be mutually beneficial and drive market expansion. Government
support for cancer research not only advances our understanding of the disease
but also fuels innovation in cancer diagnostics. Research grants and incentives
encourage companies to develop cutting-edge diagnostic technologies, leading to
a more robust market. Government initiatives aim to make healthcare more
accessible to all segments of the population. This inclusivity ensures that
even underserved communities have access to cancer diagnostics, thereby
increasing market reach.
.png)
Download Free Sample Report
Key Market Challenges
Limited Healthcare Infrastructure
One of the primary challenges in the growth of the
India Cancer Diagnostics Market is the limited healthcare infrastructure,
especially in rural and underserved areas. While major cities have advanced
diagnostic facilities, a significant portion of the population in remote
regions lacks access to even basic healthcare services, including cancer
diagnostics.
The lack of infrastructure restricts the reach of
cancer diagnostic services. Patients in rural areas may face long travel
distances and high costs to access diagnostic centers in urban areas. This
hinders early detection and timely treatment, ultimately impacting market
growth. Government initiatives to expand healthcare infrastructure,
particularly in rural areas, can help mitigate this challenge. Investments in
building diagnostic centers, telemedicine services, and mobile clinics can
extend the reach of cancer diagnostics to underserved populations.
High Cost of Diagnostic Procedures
Cancer diagnostic procedures, especially advanced
imaging and molecular tests can be expensive. Many Indians, particularly those
from low-income backgrounds, may find the cost of these procedures prohibitive.
This cost barrier can deter individuals from seeking timely cancer screenings
and diagnostic tests.
The high cost of diagnostic procedures can result
in delayed diagnosis or the avoidance of screenings altogether. This, in turn,
may lead to cancer being detected at later, less treatable stages, impacting
patient outcomes and limiting market growth. To address this challenge,
healthcare providers and diagnostic companies can explore cost-effective
diagnostic solutions and offer subsidized or affordable screening programs.
Government subsidies and health insurance schemes can also help make cancer diagnostics
more accessible to a broader population.
Lack of Awareness and Stigma
Despite efforts to raise awareness, there is still
a significant lack of understanding and awareness about cancer in many parts of
India. The cultural and social stigmas associated with the disease
persist. This lack of awareness and stigma can discourage individuals from
seeking cancer diagnostic services, even when they experience symptoms.
A lack of awareness and stigma can lead to delayed
diagnoses and missed opportunities for early detection. Public education
campaigns and efforts to reduce stigma are essential for overcoming this
challenge and promoting early cancer screenings. Government and non-government
organizations can intensify their awareness campaigns, targeting both urban and
rural populations. These campaigns should emphasize the importance of early
detection and debunk myths surrounding cancer. Community outreach and education
programs can help reduce stigma and encourage individuals to seek cancer
diagnostics when needed.
Key Market Trends
Rise in Personalized Medicine and Targeted
Therapies
Personalized medicine and targeted therapies have
gained prominence in cancer diagnostics and treatment. Advancements in
molecular diagnostics and genomic profiling have allowed healthcare providers
to tailor cancer therapies to the specific genetic characteristics of a
patient's tumor. This trend is increasingly shaping the landscape of cancer
diagnostics in India.
The adoption of personalized medicine not only
improves treatment outcomes but also drives the demand for advanced diagnostic
tests that identify specific biomarkers and genetic mutations. Diagnostic
companies are developing tests that help oncologists select the most effective
treatments for individual patients, leading to increased market growth. Liquid
biopsies, which detect circulating tumor DNA, are gaining traction for
monitoring treatment response and identifying resistance mutations. The companion diagnostics are becoming more common, guiding the use
of targeted therapies.
Telemedicine and Remote Consultations
The COVID-19 pandemic accelerated the adoption of
telemedicine and remote consultations in healthcare, including cancer
diagnostics. Telemedicine platforms and virtual consultations with oncologists
have become more accessible and accepted by patients, particularly those in
remote or underserved areas.
Telemedicine has expanded the reach of cancer
diagnostic services, allowing individuals to consult with specialists without
the need for long-distance travel. This trend enhances early detection by
ensuring that individuals from all geographical locations can access diagnostic
consultations and recommendations. Tele-oncology services provide expert
opinions and guidance for cancer diagnostics, treatment planning, and follow-up
care. Patients can undergo initial consultations and receive test results
remotely, improving the overall patient experience.
Artificial Intelligence (AI) and Machine Learning
Integration
The integration of artificial intelligence (AI) and
machine learning (ML) into cancer diagnostics is a growing trend in India.
These technologies analyze vast datasets, including medical images and
pathology reports, to assist radiologists and pathologists in diagnosing cancer
more accurately and efficiently.
AI and ML algorithms can detect subtle patterns and
anomalies in medical images, improving the accuracy of cancer diagnoses. They assist in risk prediction, early detection, and treatment
planning. The adoption of AI-driven diagnostic tools is enhancing the
capabilities of healthcare professionals and driving market growth. AI-powered
software can assist in mammography interpretations, lung nodule detection in CT
scans, and the analysis of histopathological slides. These tools expedite the
diagnostic process and reduce the risk of human error.
Segmental Insights
Product Insights
Based on product, The consumables segment emerged as the fastest-growing segment in the India cancer diagnostics market, fueled by the rising demand for cancer diagnostic reagents. These reagents are essential for key diagnostic techniques such as immunohistochemistry (IHC), in situ hybridization (ISH), and molecular diagnostics tests, all of which are crucial for the precise detection and classification of cancer.
The escalating prevalence of cancer in India has intensified the demand for advanced and reliable testing solutions, significantly boosting the consumption of consumables in diagnostic procedures. A major driver of this growth is the increasing awareness about the benefits of early cancer detection, which greatly improves patient outcomes and treatment success rates. As both patients and healthcare professionals adopt a more proactive approach to early diagnosis, the reliance on high-quality consumables continues to expand.
Additionally, government initiatives and private sector investments are strengthening diagnostic infrastructure and accelerating innovation in test development. These efforts not only enhance the accessibility of cancer diagnostic services but also foster the introduction of next-generation consumables tailored to evolving clinical needs. Together, these factors are positioning consumables as the fastest-growing segment in India’s cancer diagnostics landscape.
Type Insight
Based on type, in 2024, the in vitro diagnostics (IVD) segment emerged as the leading force in India’s cancer diagnostics market, driven by its broad applicability, growing affordability, and increasing availability across healthcare settings. IVD cancer diagnostic tests, including immunohistochemistry (IHC), in situ hybridization (ISH), and molecular diagnostics, are widely used in hospitals and diagnostic labs for detecting, classifying, and monitoring various types of cancer. These tests are known for their precision, reliability, and ability to support early detection, making them integral to cancer care protocols. One of the key factors behind the segment’s dominance is the cost-effectiveness of IVD tests compared to more complex or infrastructure-intensive methods like laboratory-developed tests (LDTs) and advanced imaging techniques. This affordability makes IVD tests more accessible to a broader patient population, especially in tier 2 and tier 3 cities where affordability and accessibility are key concerns. The increased government funding and private sector investments have led to the development and expansion of cancer diagnostic infrastructure in India. As diagnostic laboratories and healthcare providers adopt modern testing platforms, the availability and reach of IVD tests have grown significantly. These factors, combined with the rising cancer burden and public health initiatives promoting early screening, are expected to sustain the IVD segment’s strong performance in the years ahead.
Application Insight
Based on application, in 2024, the breast cancer segment emerged as the dominant player in India’s cancer diagnostics market, largely due to the high prevalence of breast cancer among women. As per the National Cancer Registry, breast cancer accounted for approximately 29% of all cancer cases in Indian women, making it the most common form of cancer affecting the female population. This high incidence has significantly increased the demand for early detection and effective diagnostic solutions. Early diagnosis of breast cancer is critical to improving survival rates and treatment outcomes. With growing awareness campaigns, both public and private, more women are now seeking regular screenings and check-ups. This shift in behavior has driven the uptake of diagnostic tests such as mammography, ultrasound, biopsy, and molecular diagnostics tailored for breast cancer detection. Government initiatives like Ayushman Bharat and targeted screening programs have increased funding and accessibility to diagnostic services. Simultaneously, the private sector is actively investing in expanding diagnostic infrastructure and innovating new technologies, including portable screening tools and AI-enabled diagnostics. These combined efforts are making breast cancer diagnostics more available, affordable, and efficient, thereby reinforcing the segment's leading position in India’s cancer diagnostics landscape.
Download Free Sample Report
Regional Insights
North India Segment emerged as the dominant region in the India Cancer Diagnostics market in 2024, holding the largest market
share in terms of value. North India, particularly the
National Capital Region (NCR) and major cities like Delhi, has historically had
a more advanced healthcare infrastructure compared to other regions. The
presence of top-tier hospitals, cancer centers, and diagnostic laboratories in
these areas has contributed to the dominance of North India in the cancer
diagnostics market. Patients from neighbouring states often travel to North
India for specialized diagnostic services. North India hosts a significant
concentration of leading healthcare institutions, research centers, and medical
colleges. These institutions often serve as hubs for cancer diagnosis,
research, and treatment. Their expertise and state-of-the-art diagnostic
facilities attract patients from across the country. North India, including the
NCR, has a relatively higher population density compared to many other regions.
The larger population base translates to a higher number of potential patients
seeking cancer diagnostic services. This factor contributes to the dominance of
North India in terms of market size. North India, particularly urban areas,
has relatively higher awareness levels about cancer and the importance of early
detection. The population in these areas often has better access
to healthcare insurance and financial resources, making them more likely to
afford advanced diagnostic tests. Leading medical institutions and research
centers in North India actively engage in cancer research and diagnostic
innovation. This environment fosters the development and adoption of
cutting-edge diagnostic technologies, further strengthening the region's
dominance in the market.
Recent Developments
- In July 2025, Bengaluru: Scientists from the Indian Institute of Science (IISc) developed a simple, glowing paper sensor that could help detect liver cancer at an early stage. The sensor used the green glow of a rare earth metal called terbium to indicate the presence of cancer markers. This innovation aimed to make early liver cancer detection more accessible and affordable through a lightweight, easy-to-use tool.
- In July 2025, the impact of artificial intelligence on health care—from cancer detection to treatment—was explored in depth. AI had already begun transforming the very fabric of the medical field, offering the promise of a 'healthier human'. This marked the second part of a three-part series that examined how AI technologies had reshaped diagnostics, personalized treatment, and overall patient care across various healthcare settings.
- In May 2025, researchers from the International Agency for Research on Cancer (IARC) and partner institutions contributed to the validation and launch of human papillomavirus (HPV) detection tests developed in India for cervical cancer screening. The results were officially announced in Delhi on 23 April 2025, in the presence of Dr. Jitendra Singh, Minister of State (Independent Charge) for the Ministry of Science and Technology of India.
- In August 2023, Bristol-Myers Squibb India
announced that it has received regulatory approval from the Drugs Controller
General of India (DCGI) for the launch of Zeposia (ozanimod), a drug for the
treatment of relapsing-remitting multiple sclerosis (RRMS). Zeposia is the
first oral, sphingosine 1-phosphate (S1P) receptor modulator to be approved in
India for the treatment of RRMS.
- In August 2023, Bristol-Myers Squibb India Private Limited. is expanding its
manufacturing capacity in Ahmedabad, India. The expansion is expected to be
completed in 2024 and will double the company's production capacity for generic
injectables.
- In September 2023, Cipla has launched the generic
version of Evusheld (tixagevimab and cilgavimab), a monoclonal antibody
cocktail for the prevention of COVID-19. Evusheld is the first monoclonal
antibody cocktail to be launched in India for the prevention of COVID-19.
Key Market Players
- Baxter Pharmaceuticals India
Private Limited.
- Bristol-Myers
Squibb India Private Limited.
- Cipla
Ltd.
- Roche
Products (India) Private Limited.
- Glenmark
Pharmaceuticals Ltd.
- Lupin Ltd
- Abbott
India Laboratories Limited
- BIO-RAD
LABORATORIES (INDIA) PRIVATE LIMITED.
- Siemens
Healthcare Private Limited.
- Thermo
Fisher Scientific India Private Limited.
|
By Product
|
By Type
|
By Application
|
By Test-Type
|
By End-User
|
By Region
|
- Instruments
- Consumables
- Services
|
|
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Lung Cancer
- Prostate Cancer
- Skin Cancer
- Blood Cancer
- Kidney Cancer
- Liver Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Others
|
|
- Hospitals
- Laboratories
- Others
|
|
Report Scope:
In this report, the India Cancer Diagnostics Market
has been segmented into the following categories, in addition to the industry
trends which have also been detailed below:
- India Cancer Diagnostics Market, By Product:
o Instruments
o Consumables
o Services
- India Cancer Diagnostics Market, By Type:
o IVD
o LDT
o Imaging
- India Cancer Diagnostics Market, By Application:
o Breast Cancer
o Colorectal Cancer
o Cervical Cancer
o Lung Cancer
o Prostate Cancer
o Skin Cancer
o Blood Cancer
o Kidney Cancer
o Liver Cancer
o Pancreatic Cancer
o Ovarian Cancer
o Others
- India Cancer Diagnostics Market, By Test-Type:
o Biopsy
o Others
- India Cancer Diagnostics Market, By End-User:
o Hospitals
o Laboratories
o Others
- India Cancer Diagnostics Market, By Region:
o North India
o South India
o East India
o West India
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the India Cancer
Diagnostics Market.
Available Customizations:
India Cancer Diagnostics market report with
the given market data, TechSci Research offers customizations according to a
company's specific needs. The following customization options are available for
the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
India Cancer Diagnostics Market is an upcoming
report to be released soon. If you wish an early delivery of this report or
want to confirm the date of release, please contact us at [email protected]